What is the ‘know-how gap’ problem and how might it impact scaling up production...

This entire article is also available as a PDF by clicking here. 1. Introduction. How relevant are concerns about intellectual property rights causing problems for...

WTO Covid-19 TRIPS Decision: Some observations

This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...

Sharing know-how/trade secrets during a pandemic: We must be planning for it now

Medicines Law & Policy has recently proposed a provision for inclusion in the draft WHO  pandemic instrument currently being discussed in Geneva (here and...

The European Commission says Covid-19 vaccines should be global public goods, but do their...

The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....

The European Parliament has now explicitly acknowledged the know-how problem too: time to include...

This technical briefing note is also available as a PDF here. We have been calling attention to the problem of sharing know-how necessary for the...

Submission to the US International Trade Commission

On 17 June 2022, World Trade Organization (WTO) Members adopted a Ministerial Decision outlining flexibilities in the WTO’s Trade Related Aspects of Intellectual Property...

European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and...

European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...

Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development

This is an excerpt from a longer report on AI, medicines development and the patent system. Download the full report here (or by clicking...

Continuing to ignore the problem of the know-how gap won’t make it go away.

The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...